Toronto’s Specific Biologics advances gene editing therapy for ALS

Toronto-based Specific Biologics, a spinout from Western University, has raised $35 million to advance a gene editing therapy aimed at treating ALS. This funding follows promising pre-clinical results, marking a significant step toward potential treatments for this fatal disease.

Originally published by gnews